Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients

Table 4

Secondary outcomes based on CRP, neutrophil, lymphocyte, LCR, and NLR

No	CRP		Neutrophil		Lymphocyte		LCR		NLR
	Before	After	Before	After	Before	After	Before	After	Before	After
1	17.30	0.94	91.30	88.80	4.30	6.60	0.25	7.02	21.23	13.45
2	22.58	1.51	85.30	88.30	9.30	4.50	0.41	2.98	9.17	19.62
3	8.57	0.95	72.50	88.10	18.30	4.30	2.14	4.53	3.96	20.49
4	9.48	1.17	90.20	82.20	4.70	10.50	0.50	8.97	19.19	7.83
5	8.99	0.56	94.00	85.20	2.60	7.70	0.29	13.75	36.15	11.06
6	7.74	6.44	82.30	81.20	8.50	10.20	1.10	1.58	9.68	7.96
7	5.79	1.98	70.60	76.80	20.60	13.90	3.56	7.02	3.43	5.53
8	4.48	0.63	73.70	80.10	18.90	12.80	4.22	20.32	3.90	6.26
9	23.00	6.10	82.60	78.80	11.90	12.80	0.52	2.10	6.94	6.16
10	5.06	5.03	71.70	92.60	17.10	4.40	3.38	0.87	4.19	21.05
Mean ± SD	10.89 ± 8.09	2.53 ± 2.36	81.42 ± 8.82	84.21 ± 5.15	19.37 ± 22.95	8.77 ± 3.76	1.64 ± 1.55	6.91 ± 6.15	11.79 ± 10.66	11.94 ± 6.30
	0.005		0.389		0.234		0.009		0.285